Ypsomed achieves retail business turnaround and increases operating profit significantly
In the preceding business year, all Ypsomed's business segments have worked effectively. To accentuate was, that the Diabetes Direct Business segment successfully turned the corner: at CHF 6 million in 2013/14, EBIT was positive for the first time following a loss of CHF 3 million in the prior year. As well as the major success enjoyed by mylife™ OmniPod®, there are two other reasons for this pleasing result: Ypsomed is growing thanks to the many years of investing in its international sales organizations, while our company can also boast extensive management and sales expertise, allowing any opportunities to be pre-empted and exploited. In the Delivery Devices segment, Ypsomed generated sales of CHF 142 million in 2013/14. Compared with the prior year, sales have risen by 3%, signaling a change in fortunes, after sales had fallen over the prior year from CHF 153 million (2011/12) to CHF 138 million (2012/13) due to expiring contracts. Higher sales volumes for SoloSTAR® components and increased earnings from the industrialization of future pen systems for pharmaceutical partners contributed amongst others to this positive growth. The segment posted an operating profit of CHF 9 million, virtually on a par with the prior year due to various effects. Overall the Ypsomed Group increased net profit in the business year 2013/14 with CHF 12 million up to CHF 14 million.
Itemized information of the financial year 2013/14, strategic as well as operative information will be disclosed in the course of the annual press conference and presentation of the annual results on May 27, 2014, after both the release of the the report of the statutory auditors and the approval by the Board of Directors.
The Ypsomed Group is a leading, independent Swiss developer and manufacturer of injection systems for selfmedication and a renowned diabetes specialist with over 25 years of experience. Founded in 2003 from the wellknown company Disetronic, today it offers insulin pumps and injection systems as well as pen needles for the treatment of diabetes, growth disorders, infertility and other therapeutic areas. Ypsomed is regarded as a leader in innovation and technology and is the preferred partner of pharmaceutical and biotech companies in the self-medication field. Ypsomed has established itself with the umbrella brands mylife™ Diabetescare and YDS™ Ypsomed Delivery Systems in retailing and in business-to-business trading. Under the brand name mylife™ Diabetescare, Ypsomed offers patients an extensive range of self-manufactured products or commercial products for the treatment of diabetes. The range from YDS™ reflects the many years of experience and competence in the field of injection systems. With an innovative and patent-protected product portfolio of pen systems and autoinjectors, which can be adapted to customer requirements; contract development and manufacturing; as well as the assembly of injection systems with medications, Ypsomed provides customer orientated product and service solutions to pharmaceutical and biotech companies worldwide.
Ypsomed has its headquarters in Burgdorf and owns several manufacturing sites in Switzerland and in the Czech Republic. Ypsomed has its own subsidiaries throughout Europe and works with leading, independent marketing partners worldwide. The Ypsomed Group has around 1,000 employees.